Pre-first fill
Treatment
Post-treatment
Support patients in their journey post-treatment by explaining processes such as:
MAVYRET Nurse Ambassadors provide product support but do not provide medical advice and will direct patients to their healthcare professional for any medical advice or questions related to treatment decisions and plans.
98%
OF PATIENTS ENROLLED IN MAVYRET PATIENT SUPPORT ARE ENGAGED WITH THEIR MAVYRET NURSE AMBASSADOR (N=1118)2
Data as of May 10, 2018. Based on enrollments through April 30, 2018.
In the office
One-page paper form sign-up is available: download it here
By phone
Phone sign-up 1-877-628-9738
Online
Registration is available at the Patient Website
A Nurse Ambassador will contact patients within one business day of enrolling in MAVYRET Patient Support.
MAVYRET is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.
WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV: Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with MAVYRET. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.
Risk of Hepatic Decompensation/Failure in Patients with Evidence of Advanced Liver Disease
Risk of Reduced Therapeutic Effect Due to Concomitant Use of MAVYRET with Certain Drugs
Most common adverse reactions observed with MAVYRET:
US-MAVY-190705